Memorializing Women on the Move: A register of migrant women landmarks in Europe.

This dataset was developed by COST Action 19112 Women on the Move (WEMov), which engages in unveiling women migrants' presence and participation in the construction of Europe. The dataset was built as a register of toponyms and monuments in the political and public landscape in Europe - such as street names, school names and parks, as well as statues and memorials - that celebrate women migrants. With the dataset we want to discover how women migrants are remembered and what kind of landmarks present these individuals who have had an episode of migration for a variety of reasons. Moreover, our aim is to make these landmarks and the stories of women migrants visible by presenting the results of the dataset in an interactive map on our website. At the moment, the dataset includes 1000 landmarks. The collection of data was based on voluntary work of scholars and students from over 40 different European countries. We have aimed for broad geographical coverage; however, some areas are better represented than others due the nature of data collection. The collection of data is an ongoing process and therefore the dataset in Nakala repository, to which this data note refers, presents the situation in July 2023. Updated versions of the dataset will be made available in Nakala and we will download new landmarks to our interactive map on a regular basis. The selected landmarks and migrant trajectories feature cross-community or cross-cultural migration. They show both typical and exceptional forms of mobility and present women of different age, profession, social status and migration status. This intersectionality of the project and the dataset highlights not only the richness of these landmarks and their value for scholarship but also the wide spectrum of migrant women and their contribution to society.

The dataset shows landmarks in memory of migrant women. These landmarks are the result of political decisions at one point in history to honour these women. The landmarks are tangible and denominated, available in the public space, such as buildings, streets, parks, monuments or gravestones. This collection of data shows how all these landmarks keep the memory of these migrant women alive in daily life. In the dataset we have 1000 landmarks from all over Europe. You can view them on our website.

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer.

PURPOSE: Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC). This trial was undertaken to determine whether adjuvant treatment with the metalloproteinase inhibitor marimastat could prolong survival in responding patients with SCLC after chemotherapy. PATIENTS AND METHODS: SCLC patients in complete or partial remission were eligible. They were stratified by radiotherapy (early, late, or none), stage (extensive or limited), response (complete or partial), and cooperative group (National Cancer Institute of Canada-Clinical Trials Group or European Organization for Research and Treatment of Cancer). They were randomized to receive marimastat 10 mg or placebo orally bid for up to 2 years. RESULTS: There were 532 eligible patients (266 marimastat and 266 placebo). Stage was limited for 279 patients (52%) and extensive for 253 (48%). Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection. The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P =.81). Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P =.90) Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat). Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity. Patients on marimastat had significantly poorer quality of life at 3 and 6 months. CONCLUSION: Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.

Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis.

PURPOSE: The effects of age and comorbidity on treatment and outcomes for patients with limited stage small-cell lung cancer (L-SCLC) are unclear. This study analyzes relapse and survival in a community-based population with L-SCLC according to age and comorbidity. METHODS: A retrospective review was performed on 174 patients with L-SCLC referred to the British Columbia Cancer Agency, Vancouver Island Centre, between January 1991 and December 1999. Patient and treatment characteristics, disease response, relapse, and survival were compared among three age cohorts: <65 years (n = 55, 32%), 65-74 years (n = 76, 44%), and > or =75 years (n = 43, 25%); and according to Charlson comorbidity scores 0, 1, and > or =2. Multivariate analysis was performed to identify independent prognostic factors associated with treatment response and survival. RESULTS: Patient factors that significantly differed with age were functional status classified by Eastern Cooperative Oncology Group performance status and number of comorbidities. Increasing age was significantly associated with fewer diagnostic scans. Combined modality chemoradiotherapy (CRT) was given in 86%, 66%, and 40% of patients ages <65, 65-74, and > or =75 years, respectively, (p <0.0001). Thoracic irradiation use was comparable among the age cohorts (p >0.05), but chemotherapy use varied significantly with less intensive regimens, fewer cycles, and lower total doses with advancing age (p <0.05). Prophylactic cranial irradiation (PCI) was used in 41 patients, only 3 of whom were age >70 years. Overall response rates to primary treatment significantly decreased with advancing age: 91%, 79%, and 74% in patients ages <65, 65-74, and > or =75 years, respectively (p = 0.014). Treatment toxicity and relapse patterns were similar across the age cohorts. Overall 2-year survival rates were significantly lower with advancing age: 37%, 22%, and 19% (p = 0.003), with corresponding median survivals of 17, 12, and 7 months among patients ages <65, 65-74, and > or =75 years, respectively. On multivariate analysis, age and Charlson comorbidity scores were not significantly associated with treatment response and survival. Independent prognostic factors favorably associated with survival were good performance status, normal lactate dehydrogenase, absence of pleural effusion, and > or =four cycles of chemotherapy. CONCLUSION: Increasing age was associated with decreased performance status and increased comorbidity. Older patients with L-SCLC were less likely to be treated with CRT, intensive chemotherapy, and PCI. Treatment response and survival rates were lower with advancing age, but this may be attributed to poor performance status and suboptimal treatment rather than age.

Dosagem de creatinina: fatores de erro na reação de Jaffé / Creatinine dosage: error factors in the Jaffé Reaction

Estudamos o mecanismo da reação de Jaffé para a determinação da creatinina humana, utilizando os métodos cinético e ponto-final. Foi analisada a magnitude de interferência nas constantes físicas (tempo e temperatura de incubação) e no equilíbrio da reação, obtendo-se valores subestimados a 25'C nos 2 métodos estudados. Os resultados a 30'C são coerentes com os valores de referência descritos na literatura. A hiperglicemia interfere mais significativamente na reação de ponto-final, elevando os resultados de creatinina a partir de 290 mg%. O método cinético mostrou-se bastante eficaz na dosagem da creatinina sérica discriminando valores sem interferência de substâncias redutoras e com reprodutibilidade compatível às melhores técnicas laboratoriais (AU).

Fenilcetonúria / Phenylketonuria

O interesse pelas doenças genéticas têm aumentado nos países de primeiro mundo à medida que o controle das doenças infecciosas e sociais torna-se cada vez mais efetivo. Dados recentes mostram que cerca de 50 por cento das mortes perinatais ocorrem por causas genéticas. Além disso, 1/3 das internaçöes de crianças em hospitais pediátricos e 10 por cento das doenças crônicas de adultos também säo atribuídas a fatores genéticos. Estima-se que temos cerca de 50.000 a 100.000 genes, dispersos ao longo de 23 pares de cromossomos, responsáveis por nossas características hereditárias. Por outro lado, já säo conhecidas cerca de 6.000 doenças genéticas, a maioria ainda sem tratamento especifico. O grande desafio dos geneticistas tem sido e de identificar os nossos genes, compreender quais säo os mecanismos que causam patologias genéticas, e enquanto näo houver tratamentos eficazes, prevenir o nascimento de novos afetados. Aminoacidopatias e organopatias säo os erros inatos do metabolismo, mais comuns, do período neonatal. Na Alemanha, aproximadamente 1:15000 dos recém-nascidos säo diagnosticados como portadores de aminoacidopatias e aproximadamente 1:9000 säo diagnosticados como portadores de organoacidopatias. Especialmente no caso das organoacidopatias há evidências substanciais que este número deve estar subestimado

Frutosamina: uma revisäo dos últimos dez anos / Fructosamine: a review for the last ten years

A manutençäo da taxa de glicose sanguínea täo próxima quanto possível dos níveis normais tem sido amplamento aceita como um bom índice de acompanhamento, podendo reduzir significativamente as sequelas do diabetes. Medidas diárias múltiplas da glicemia näo säo frequentemente um caminho prático no controle do diabético, embora pudessem ser consideradas como o melhor método de controle. Durante a década de 70, diversas técnicas para a mensuraçäo das hemoglobinas glicadas tornaram-se acessíveis à grande maioria dos laboratórios, fornecendo uma indicaçäo retrospectiva dos níveis de glicose sanguínea das últimas quatro semanas e têm sido largamente adotadas como uma maneira usual deste mesmo controle diabético. A maioria das técnicas tentam medir a HbAIc, originalmente descrita como a mais abundante das fraçöes glicadas da hemoglobina que se encontram aumentadas nos diabéticos. Durante a última década vários métodos foram desenvolvidos para mensurar outras proteínas glicadas além da HbAIc. A descoberta de que outras proteínas séricas säo glicadas em caminhos análogos ao da hemoglobina despertou muito interesse quanto à sua aplicaçäo clínica. A albumina glicada tem sido indicada como um índice para o controle glicêmico num tempo de duas, três semanas, um período menor do que o da hemoglobina glicada, mas suficiente para ser adotada como controle

Avaliaçäo crítica da interferência da bilirrubina na dosagem de creatinina sérica pela reaçäo de Jaffé / Critical evaluation of bilirubin interference in the Jaffé reaction for serum creatinine determination

Estudamos a deteminaçäo da creatinina em "pools" de soro (normal e alterado) acrescidos de quantidades conhecidas de bilirrubina e também em soros ictéricos de pacientes, através da reaçäo de Jaffé, utilizando os métodos de ponto-final e cinético. Verificamos a interferência negativa da bilirrubina na dosagem cinética de creatinina, que näo foi observada na reaçäo de ponto-final. A reaçäo cinética, entretanto, pode ser utilizada em soros ictéricos desde que haja uma inversäo da ordem de adiçäo dos reagentes, com pré-incubaçäo das amostras com NaOH 0,5 N

Determinaçao das frutosaminas sericas por colorimetria: comparaçao entre a tecnica manual e a semi-automatizada em ABA-100 / Colorimetric determination of serum fructosamine: comparison of the manual and automated (ABA-100) assays

A determinaçao das frutosaminas sericas e um parametroadicional de grande importancia no controle dadiabetes, permitindo o monitoramento do estado glicemico do paciente nas duas ultimas semanas. Sua qualificaçao porcolorimetria tem sido feita atraves da reduçao do azul denitrotetrazolio (NBT), empregando-se normalmente como padraoo 1-deoxi-1-morfolino frutoso (DMF) em soluçao aquosa debumina a 4%. Nosso objetivo foi comparar os resultados das frutosaminas sericas por metodos colorimetrico cinetico manual e semi-automatizado, utilizando-se neste ultimo,alem do DMF, um padrao secundario de soro humano de concentraçao conhecida. A glicemia foi determinada pelo metodo da hexoquinase o observamos no tratamento estatistico que os metodos para a determinaçao das frutosaminas sao semelhantes quando utilizamos dois tipos de padroes no semi-automatizado.

Mucoproteínas: novas contribuiçoes para um problema laboratorial / Mucoproteins: new assessments for a laboratorial problem

O objetivo do presente trabalho foi avaliar a influência da concentraçäo do ácido perclórico e da temperatura de desproteinizaçäo, na determinaçäo das mucoproteínas séricas. Como o doseamento das mucoproteínas possui importância clínica no acompanhamento de doenças infecciosas e de vários distúrbios metabólicos, exige-se, desta forma, um controle minucioso de fatores externos que possam interferir na sua quantificaçäo.

Controle de qualidade interlaboratorial dos métodos utilizados em bioquímica clínica, na rede do Instituto Adolfo Lutz / An interlaboratotial quality control of the utilized methods in clinical biochemistry, in the Adolfo Lutz Institute branch

Este trabalho propöe a utilizaçäo de um "pool" de soro controle normal (SCN) e de um alterado (SCA) preparado pela adiçäo de quantidades de substâncias químicas a serem analisadas. A concentraçäo dos constituintes a cada "pool" foi estabelecida pela mensuraçäo em diferentes laboratórios clínicos.Estes "pools" foram usados como um sistema controle para o estudo da precisäo e exatidäo, servindo para indicar a presença de erros, podendo alertar os analistas para falhas existentes na metodologia e aparelhagem